In an era of persistent inflation and volatile markets, I find myself asking an important question for biotech companies looking to preserve and optimize the capital they have: Could allocating a portion of treasury cash to Bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success?| christianangermayer.substack.com
I am very happy to announce that within the recently completed capital raise of atai Life Sciences (Nasdaq: ATAI) of a total of USD 63.25 million (in gross proceeds, including full exercise of the “greenshoe”, less costs), my family office, Apeiron Investment Group| christianangermayer.substack.com
All major psychedelics – and more - in just one company| christianangermayer.substack.com
Structural societal changes are about to fundamentally change the future of biotech, pharma, and the wellness industry for the better.| christianangermayer.substack.com